Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway

NCT01601184 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT01601184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01601184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Lead sponsor
Centre Leon Berard
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2012
Completion date
October 31, 2017
Enrollment
24 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

activation of the sonic hedgehog (shh) pathway, histologically confirmed medulloblastoma